DocWire News Editors

DocwireNews

Patients with bladder outlet obstruction (BOO) who do not respond to pharmacotherapy treatment may undergo surgery. In favor of cost reduction and minimally invasive outlet procedures, patients may be treated in an ambulatory surgical center as opposed to the traditional inpatient setting. In the present study, researchers evaluated risk factors associated with 30-day revisits and costs in postoperative BOO patients. The findings of the study were presented at the 2019 American Urological Association Annual Meeting.The study included all-payer data from the 2014 Healthcare Cost and Utilization Project (HCUP) State Databases from Florida and New York. Patients who underwent an index transurethral resection (TURP), laser/photovaporization (PVP), or thermotherapy (TUMT/TUNA) were eligible for inclusion. Researchers assessed patient demographics, regional data, 30-day revisit rates, and total charges&mdash;which were converted to costs&mdash;associated with revisit; they used multivariate logistic regression analysis adjusted for facility clustering to determine risk factors associated with 30-day revisit.The final analysis included 15,094 BOO patients; 1,444 (9.6%) sustained a 30-day revisit. The median 30-day revisit cost was $4,263.43. Patients treated in the inpatient setting were more likely to require 30-day revisit compared to those who underwent ambulatory procedures (12% vs. 8.1%, P &lt; 0.001). The following risk factors were associated with increased risk of 30-day revisit: older age (odds ratio [OR] 1.01, 95% confidence interval [CI] 1.00-1.02, P = 0.002), higher Charlson Comorbidity Index score (CCI &ge; 2 vs. 0: OR 1.75, 95% CI 1.49-2.04, P &lt; 0.001), payer status (private vs. Medicare: OR 0.77, 95% CI 0.62-0.95, P = 0.02), median household income (&ge; $66,000 vs. &lt; $40,000: OR 0.72, 95% CI 0.57-0.93, P = 0.004), and index care setting (ambulatory vs. inpatient: OR 0.48, 95% CI 0.40-0.57, P &lt; 0.001).The authors concluded that the risk of 30-day revisit was significant among BOO patients treated in the inpatient setting as well as those with Medicare. According to the researchers, &ldquo;Our findings have important policy implications in the setting of recent value-based purchasing efforts, which seek to reduce variation in non-clinical sources of perioperative costs and outcomes.&rdquo;Friedlander D, Krimphove M, Cole A, et al. Effect of Index Surgical Care Setting on 30-day Revisit Rates and Associated Costs Following Outlet Procedure for Symptomatic Benign Prostatic Hyperplasia. Presented at the 2019 American Urological Association Annual Meeting.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

30-day Costs, Revisit Rates After Operative Bladder Outlet Obstruction Treatment

Spring 2019 Conference coverage

Patients with bladder outlet obstruction (BOO) who do not respond to pharmacotherapy treatment may undergo surgery. In favor of cost reduction and minimally invasive outlet ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe